Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03555188
Other study ID # 15/74/01
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 29, 2018
Est. completion date September 10, 2020

Study information

Verified date August 2023
Source University of Leeds
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A placebo controlled study to determine the efficacy and mode of action of ondansetron in the treatment of irritable bowel syndrome with diarrhoea.


Description:

Irritable bowel syndrome (IBS) affects around 10% of the population and accounts for 1.8 million consultations/year in primary care in England and Wales (0.6 million patients). Around one third of patients meet the criteria for IBS with diarrhoea (IBS-D) and despite its high prevalence, there is no satisfactory treatment at present. Loperamide is currently used to reduce bowel frequency, however it does not improve symptoms such abdominal pain. Other symptoms of IBS-D include frequent, loose, or watery stools with associated urgency, which can severely limit socialising, travelling, and eating out, resulting in a reduced quality of life and work productivity. The primary aim of the study is to determine the effectiveness and safety of the use of ondansetron in patients with the symptoms of IBS-D including urgency, looseness of stool, frequency of defecation and abdominal discomfort. Ondansetron belongs to a class of drug known as 5HT3RAs and a recent meta-analysis shows that 5HT3RAs is an effective treatment for IBS-D, improving stool consistency and reducing frequency and urgency of defecation. 400 patients with IBS-D will be randomised on a 1:1 basis to receive either Ondansetron or Placebo. Both treatments will be administered in oral doses of between 4-24mg daily for 12 weeks. Dose titration will be undertaken in the first two weeks of the study to avoid constipation. The primary outcome of response will be assessed at 12 weeks post randomisation using patient reported data on daily stool frequency and abdominal pain. If ondansetron is effective in the trial, it could easily be widely adopted since it is an inexpensive, safe, and generic drug. By providing an effective treatment, it could not only reduce patient symptoms, but also reduce costs of repeated referral and investigation.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date September 10, 2020
Est. primary completion date August 3, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: 1. Written (signed and dated) informed consent. 2. Considered fit for study participation. 3. Meeting Rome IV criteria for IBS-D 4. Aged = 18 years 5. Undergone standardised workup to exclude the following alternative diagnoses: 1. Microscopic colitis (colonoscopy or flexible sigmoidoscopy), 2. Bile acid diarrhoea (SeHCAT results of > 10%, C4 results of <19 ng/ml or failed 1 week trial of a bile acid binding agent [colestyramine 4g t.d.s. , colesevelam 625mg t.d.s. or equivalent]) within previous 5 years, Note: Cholecystectomy will not be an exclusion criteria if bile acid diarrhoea has been excluded. Patients with SeHCAT values of 5-10% will be eligible if they fail to respond to a 1 week trial of bile acid binding agent (see above) 3. Lactose malabsorption. 4. Coeliac disease (tTG or duodenal biopsy) 6. Patients of child bearing potential or with partners of child bearing potential must agree to use methods of medically acceptable forms of contraception during the study and for 90 days after completion of study drug, (e.g. implants, injectable, combined oral contraceptives, barrier methods, true abstinence (when this is in line with the preferred and usual lifestyle of the patient) or vasectomised partners). 7. For women of child bearing potential, a negative pregnancy test should be performed within 72 hours of confirmation of eligibility. 8. Weekly average worst pain score >= X on a 0 to 100 point scale <<redacted to prevent patient bias>>. 9. Any stools with a consistency of X on the Bristol Stool Form score (BSFS) for X day per week<<redacted to prevent patient bias>>. Exclusion Criteria: 1. Gastrectomy 2. Intestinal resection 3. Other known organic GI diseases (e.g. Inflammatory bowel disease - Crohns disease, Ulcerative colitis.) 4. Unable or unwilling to stop restricted medication including regular loperamide, antispasmodics (e.g. buscopan, mebeverine, peppermint oil, alverine citrate), eluxadoline, tricyclic antidepressant doses >30mg/day or other drugs likely in the opinion of the investigator to alter bowel habit. These medicines should be discontinued for a 7 day washout period prior to registration. Note: Intermittent loperamide will be permitted but only as rescue medication 5. QTc interval =450msec for men and =470msec for women. Assessed within the last 3 months by a 12-lead ECG. 6. Previous chronic use of ondansetron or contraindications to it (rare as per BNF) 7. Pulse, Blood pressure, FBC or LFTs outside the normal ranges according to the site's local definition of normal. Assessed within the last 3 months.Note: Minor rises in ALT (<2 x upper limit of normal) will be acceptable but the patient's GP will be informed if they remain elevated at end of the study. 8. Women who are pregnant or breastfeeding 9. Patients currently participating or who have been in an IMP trial in the previous three months where the use of the IMP may cause issues with the assessment of causality in this study. 10. Currently taking SSRIs or tricyclic antidepressants (unless at a stable dose for at least 3 months and with no plan to change the dose during the study). 11. Currently taking and unwilling or unable to stop any of the prohibited medications.* *Prohibited medications - Apomorphine & tramadol which interact with ondansetron. Caution should be taken with patients on QT prolonging drugs and cardio toxic drugs. These patients should be reviewed by the PI to determine if they are suitable for the study. 12. Patients with stools of consistency X on the Bristol Stool Form score (BSFS) for X days a week <<redacted to prevent patient bias>>.

Study Design


Intervention

Drug:
Ondansetron
Ondansetron is a highly selective receptor antagonist (5-HT3RA)

Locations

Country Name City State
United Kingdom Barnsley Hospital NHS Foundation Trust Barnsley
United Kingdom Sandwell and West Birmingham Hospitals NHS Trust Birmingham
United Kingdom County Durham and Darlington NHS Foundation Trust Durham
United Kingdom Westen General Hosptal, Edinburgh Edinburgh
United Kingdom Leeds Teaching Hospitals NHS Trust Leeds
United Kingdom London North West NHS Foundation Trust London
United Kingdom Queen Mary, University of London London
United Kingdom University College London Hospitals NHS Foundation Trust London
United Kingdom Salford Royal Hospital Manchester
United Kingdom University Hospital of South Manchester Manchester
United Kingdom SouthTees Hospitals NHS FoundationTrust Middlesbrough
United Kingdom Nottingham University Hospitals NHS Trust Nottingham
United Kingdom Royal Hallamshire Hospital Sheffield
United Kingdom University Hospitals of North Midlands NHS Trust Stoke

Sponsors (16)

Lead Sponsor Collaborator
University of Leeds Barnsley Hospital NHS Foundation Trust, Barts & The London NHS Trust, County Durham and Darlington NHS Foundation Trust, Flinders University, London North West Healthcare NHS Trust, Manchester University NHS Foundation Trust, National Institute for Health Research, United Kingdom, NHS Lothian, Queen Mary University of London, Sandwell & West Birmingham Hospitals NHS Trust, Sheffield Teaching Hospitals NHS Foundation Trust, The Leeds Teaching Hospitals NHS Trust, University College London Hospitals, University Hospitals of North Midlands NHS Trust, University of Manchester

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Gunn D, Topan R, Barnard L, Fried R, Holloway I, Brindle R, Corsetti M, Scott M, Farmer A, Kapur K, Sanders D, Eugenicos M, Trudgill N, Whorwell P, Mclaughlin J, Akbar A, Houghton L, Dinning PG, Aziz Q, Ford AC, Farrin AJ, Spiller R. Randomised, placebo-c — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Colonic transit Colonic Transit study to determine if ondansetron slows colonic transit. 12 weeks
Other Ondansetron and cyclical retrograde propagated contractions in the sigmoid colon High resolution colonic manometry at baseline and week 12 12 weeks
Other Ondansetron and rectal compliance/pressure thresholds for pain/urgency. Barostat assessment at baseline and week 12 12 weeks
Other Does ondansetron reduce total faecal bile acids and total tryptase and does the reduction correlate with changes in urgency? Stool samples collected at baseline and week 12 12 weeks
Other Do polymorphisms in the TPH-1 gene predict response to ondansetron and does this alter 5-HT or TPH1-mRNA Bloods and biopsies taken at baseline and week 12 12 weeks
Primary Weekly responder for abdominal pain and stool consistency Measured at 12 weeks post randomisation and defined, as recommended by the FDA, as patient being a weekly responder for BOTH pain intensity AND stool consistency for at least 6 weeks in the 12 week treatment period. 12 weeks
Secondary Stool Frequency For the endpoint analysis, the mean number of stools per day over the last month (weeks 9-12) will be used. 12 weeks
Secondary Stool Consistency Defined as number of days per week with at least 1 loose stool and the average stool consistency over the last month (weeks 9-12) 12 weeks
Secondary Urgency of defecation The mean daily urgency score over last month (weeks 9-12) 12 weeks
Secondary Satisfactory relief of IBS symptoms Defined as satisfactory relief of IBS symptoms for at least 6 out of 12 weeks 12 weeks c
Secondary Functional dyspepsia SF-LDQ questionnaire at week 0 and week 12 This information is collected via a questionnaire which asks the patient about any symptoms associated with IBS that they may be experiencing. This information is collected at baseline (week 0) and again after treatment (week 12).
Secondary IBS Symptom Severity Scale Irritable Bowel Syndrome Symptom Severity Scale questionnaire which asks patients about their IBS symptoms such as abdominal pain etc. The patients will provide yes/no answer or a score on a 0-100 scale with 0 being the minimum amount and 100 being define as quite severe/definitely. This information is collected at baseline (week 0) and again after treatment (week 12).
Secondary Rescue Medication The total number of days taken loperamide throughout the 12 weeks 12 weeks
Secondary Abdominal pain score The mean daily pain score over the last month (weeks 9-12) 12 weeks
Secondary Hospital Anxiety and Depression Scale Hospital Anxiety and Depression Scale questionnaire. This information is collected via a questionnaire which asks the patient about their general overall feelings. It asks a variety of question and the patient is to tick the box beside the reply that is closest to how they feel. Each question has 1 of 4 potential replies (feelings) that vary depending on the nature of the question. This information is collected at baseline (week 0) and again after treatment (week 12).
Secondary IBS Quality of life summary score IBS-QOL questionnaire at 0 and 12 weeks This information is collected via a questionnaire which asks the patient about the quality of their life. This information is collected at baseline (week 0) and again after treatment (week 12).
Secondary Stool frequency post treatment The mean number of stools per day for 1 months after treatment (weeks 13-16) 4 weeks
Secondary Stool consistency post treatment The mean daily stool consistency over 1 month (weeks 13-16) . 4 weeks
Secondary Urgency of defecation post treatment The mean daily urgency score over 1 month post treatment (weeks 13-16). 4 weeks
Secondary Abdominal pain post treatment The mean daily pain score over 1 month (weeks 13-16) 4 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05118243 - Innovative Tools to Produce Legume-based Foods for Increased Consumer Acceptance N/A
Completed NCT04422327 - The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome Phase 1/Phase 2
Recruiting NCT05178017 - Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS) N/A
Completed NCT05197413 - Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms N/A
Completed NCT04905524 - Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP) N/A
Recruiting NCT06297785 - Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS) N/A
Recruiting NCT05874830 - The Optimal Route of Fecal Microbiota Transplantation for Irritable Bowel Syndrome N/A
Active, not recruiting NCT04723056 - Zemedy Application for Irritable Bowel Syndrome N/A
Completed NCT05565612 - Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome N/A
Recruiting NCT03131414 - The IMAGINE-SPOR CIHR Chronic Disease Network
Completed NCT03333291 - Fecal Transplantation in Patients With IBS N/A
Completed NCT03449628 - L. Casei DG® in Patients With Irritable Bowel Syndrome. N/A
Recruiting NCT06215222 - Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
Completed NCT05016596 - Postprandial Lipids in IBS and Nutritional Treatment N/A
Recruiting NCT04760353 - The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome N/A
Completed NCT06426745 - Split-dose Versus Single-dose Bowel Preparation for Colonoscopy N/A
Recruiting NCT04217733 - Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome Phase 3
Completed NCT03178877 - The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors N/A
Recruiting NCT05990764 - Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS) N/A
Completed NCT03948854 - Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients N/A